Tag: Aurobindo Pharma

May 31, 2017 Off

FDA approves attention-deficit/hyperactivity disorder drug

Apotex, Teva Pharmaceuticals USA, Aurobindo Pharma and Glenmark Pharmaceuticals have won FDA’s approval to market atomoxetine in multiple strengths to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

December 22, 2015 Off

FDA approves India’s Aurobindo’s generic version of Alcon’s Patanol

By Dino Mustafić

Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% which makes the product is ready for launch.